Pneumonia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AL}} | {{CMG}}; {{AE}} {{AL}} | ||
==Overview== | ==Overview== | ||
Linezolid was compared to vancomycin for the treatment of | [[Linezolid]] was compared to [[vancomycin]] for the treatment of [[ventilator-associated pneumonia]], and showed cost-effectiveness as an alternative to [[vancomycin]] treatment as it had a higher cure rate and prices per treatment were similar.<ref name="pmid14707572">{{cite journal| author=Shorr AF, Susla GM, Kollef MH| title=Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. | journal=Crit Care Med | year= 2004 | volume= 32 | issue= 1 | pages= 137-43 | pmid=14707572 | doi=10.1097/01.CCM.0000104110.74657.25 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14707572 }} </ref><ref name="pmid19277465">{{cite journal| author=De Cock E, Krueger WA, Sorensen S, Baker T, Hardewig J, Duttagupta S et al.| title=Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. | journal=Infection | year= 2009 | volume= 37 | issue= 2 | pages= 123-32 | pmid=19277465 | doi=10.1007/s15010-008-8046-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19277465 }} </ref> One study reported that oropharingeal decontamination decreased the incidence of [[ventilator-associated pneumonia]] from 4% to less than 1% in the studied population. The cost of the intervention was less than $2500. <ref name="pmid14707570">{{cite journal| author=van Nieuwenhoven CA, Buskens E, Bergmans DC, van Tiel FH, Ramsay G, Bonten MJ| title=Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units. | journal=Crit Care Med | year= 2004 | volume= 32 | issue= 1 | pages= 126-30 | pmid=14707570 | doi=10.1097/01.CCM.0000104111.61317.4B | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14707570 }} </ref> | ||
==References== | ==References== | ||
Revision as of 21:19, 17 December 2014
|
Pneumonia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pneumonia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Pneumonia cost-effectiveness of therapy |
|
Risk calculators and risk factors for Pneumonia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
Linezolid was compared to vancomycin for the treatment of ventilator-associated pneumonia, and showed cost-effectiveness as an alternative to vancomycin treatment as it had a higher cure rate and prices per treatment were similar.[1][2] One study reported that oropharingeal decontamination decreased the incidence of ventilator-associated pneumonia from 4% to less than 1% in the studied population. The cost of the intervention was less than $2500. [3]
References
- ↑ Shorr AF, Susla GM, Kollef MH (2004). "Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin". Crit Care Med. 32 (1): 137–43. doi:10.1097/01.CCM.0000104110.74657.25. PMID 14707572.
- ↑ De Cock E, Krueger WA, Sorensen S, Baker T, Hardewig J, Duttagupta S; et al. (2009). "Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany". Infection. 37 (2): 123–32. doi:10.1007/s15010-008-8046-7. PMID 19277465.
- ↑ van Nieuwenhoven CA, Buskens E, Bergmans DC, van Tiel FH, Ramsay G, Bonten MJ (2004). "Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units". Crit Care Med. 32 (1): 126–30. doi:10.1097/01.CCM.0000104111.61317.4B. PMID 14707570.